English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objectives  The study hypothesis was that a target‐specific anticoagulant would allow successful home treatment of selected patients with deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ) diagnosed in two urban emergency departments ( ED s).    Methods  A protocol was established for treating low‐risk  DVT  or  PE  patients with rivaroxaban and clinic, follow‐up at both 2 to 5 weeks, and 3 to 6 months. Patients were determined to be low‐risk by using a modified version of the Hestia criteria, supplemented by additional criteria for patients with active cancer. Acceptable outcome rates were defined as venous thromboembolism ( VTE ) recurrence ≤ 2.1% or bleeding ≤ 9.4% during treatment.  VTE  recurrence required positive imaging of any  VTE . The International Society of Thrombosis and Hemostasis definition of major or clinically relevant nonmajor bleeding was used.    Results  From March 2013 through April 2014, a total of 106 patients were treated. Seventy‐one (68%) had  DVT , 30 (28%) had  PE , and five (3%) had both, representing 51% of all  DVT s and 27% of all  PE s diagnosed in both  ED s during the period of study. The 106 patients have been followed for a mean (± SD ) of 389 (±111) days (range = 213 to 594 days). No patient had  VTE  recurrence, and no patient had a major or clinically relevant bleeding event while on therapy (none of the 106, 0%, 95% confidence interval [ CI ] = 0% to 3.4%). However, three patients 2.8% (95%  CI  = 1% to 8%) had recurrent  DVT  after cessation of therapy.    Conclusions  Patients diagnosed with  VTE  and immediately discharged from the  ED  while treated with rivaroxaban had a low rate of  VTE  recurrence and bleeding.

academic emergency medicine

Immediate Discharge and Home Treatment With Rivaroxaban of Low‐risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One‐year Preplanned Analysis